Swiss contract drug manufacturer Lonza set new mid-term targets and confirmed its 2026 outlook on ​Wednesday ahead of its capital markets day, ‌while saying third-quarter performance was in line with expectations across its business areas.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in